Coating Technology offers Improved Lens Wettability for Patients with Challenging Vision Needs
BRIDGEWATER, N.J., Feb. 13, 2019 /PRNewswire/ -- Bausch +
Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC), today
announced it has received 510(k) clearance for use of the Tangible® Hydra-PEG® custom contact lens coating technology with some
of its leading Boston® gas permeable (GP) materials, the Boston XO®, Boston XO2®, Boston EO® and
Boston ES® lenses, including those utilized in the Zenlens™ scleral lens family. Designed to address contact lens discomfort and
dryness, the Tangible® Hydra-PEG® is a high-water polymer coating that is bonded to the surface of a contact lens. With this
coating technology, eye care professionals have the opportunity to enhance contact lens customization for their patients using
these Bausch + Lomb lens offerings.
"The approval of the Hydra-PEG coating technology allows eye care professionals to offer improved lens wettability when using
some of our key Boston® GP materials or Zenlens™ scleral lenses, which demonstrates our ongoing
commitment to bringing advancements that help meet the challenging vision needs of this patient segment," said Joe Gordon, U.S. President, Bausch + Lomb. "We continue to provide eye care professionals innovative specialty
contact lens materials and support through our Boston® brand of products, which have
been available for decades."
In June 2018, Bausch + Lomb entered into a worldwide licensing agreement with Tangible Science,
LLC, a company whose mission is to create technologies that improve the contact lens wearing experience, to offer the Tangible
Science Hydra-PEG® advanced contact lens coating technology on specific materials and lenses from its specialty contact lens
business.
"Specialty contact lenses and the ability to offer customizable solutions are important for patients with challenging visual
needs," said Maria K. Walker, O.D., FAAO, FSLS, visiting professor, University of Houston College of Optometry, Houston. "The availability of the
Tangible® Hydra-PEG® coating with Bausch + Lomb Specialty Vision Products will enable practitioners to offer patients additional
solutions for their demanding visual requirements."
For more information on the Bausch + Lomb Specialty Vision Products portfolio, visit www.bauschsvp.com.
About Bausch + Lomb
Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies Inc.,
is a leading global eye health organization that is solely focused on helping people see better to live better. Its core
businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses,
lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most
comprehensive product portfolios in the industry, which is available in more than 100 countries. For more information, visit
www.bausch.com.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care
products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily
in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an
innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.
Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words
"anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential,"
"target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and
beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and
uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in the Company's
other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are
incorporated herein by reference. In addition, certain material factors and assumptions have been applied in making these
forward-looking statements, including that the risks and uncertainties outlined above will not cause actual results or events to
differ materially from those described in these forward-looking statements. The Company believes that the material factors and
assumptions reflected in these forward-looking statements are reasonable, but readers are cautioned not to place undue reliance
on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health
undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of
this news release or to reflect actual outcomes, unless required by law.
Bausch + Lomb, Boston, Boston XO, Boston XO2, Boston EO,
Boston ES, Zenlens and Zen RC are trademarks of Bausch & Lomb Incorporated or its affiliates. Tangible
Science, Tangible and Hydra-PEG are trademarks of Tangible Science, LLC.
© 2019 Bausch & Lomb Incorporated
MTB.0055.USA.19
Investor Contact:
Arthur Shannon
arthur.shannon@bauschhealth.com
(514) 856-3855
(877) 281-6642 (toll free)
Media Contact:
Lainie Keller
lainie.keller@bauschhealth.com
(908) 927-0617
View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch--lomb-receives-510k-clearance-for-use-of-the-tangible-hydra-peg-custom-contact-lens-coating-technology-on-several-of-its-boston-gas-permeable-lens-materials-and-zenlens-family-of-scleral-lenses-300794669.html
SOURCE Bausch Health Companies Inc.